REDX.L Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 18:28):

Stats
Tagesvolumen	20.48M
Durchschnittsvolumen	838 041
Marktkapitalisierung	58.35M
EPS	£-0.0370 ( Q4 \| 2023-09-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.500 (Sector) 0 (Industry) 0
ATR14	£2.03 (13.52%)

AMYT.L -11.73%

APH.L -0.45%

AVCT.L -1.00%

AZN.L -0.40%

BMK.L 2.34%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -0.80%

DPH.L 0.05%

EAH.L 3.20%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -4.29%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 3.33%

GNS.L 1.44%

GSK.L -0.46%

HCM.L -0.36%

HEMO.L -2.90%

HIK.L -0.53%

IMM.L 4.81%

INDV.L -0.40%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.27%

PRM.L -4.82%

PRTC.L -0.23%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 10.11%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 4.05%

STX.L 2.70%

TILS.L 8.33%

TRX.L -2.06%

VAL.L 0.00%

VEC.L 0.00%

Volumen Korrelation

Lang: -0.34 (neutral)

Kurz: 0.93 (very strong)

Signal:(57.69) Expect same movement, but be aware

Redx Pharma PLC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Redx Pharma PLC Korrelation - Währung/Rohstoff

0.64
( weak )

0.50
( neutral )

0.66
( moderate )

-0.01
( neutral )

-0.63
( weak negative )

0.11
( neutral )

Redx Pharma PLC Finanzdaten

Annual	2023
Umsatz:	£4.20M
Bruttogewinn:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
Umsatz:	£4.20M
Bruttogewinn:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
Umsatz:	£18.69M
Bruttogewinn:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
Umsatz:	£10.04M
Bruttogewinn:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.